Dr. Daniel Maspoch is an ICREA Research Professor and Leader of the Supramolecular NanoChemistry & Materials Group at ICN2.
He is a chemist who has always maintained a rewarding balance between fundamental and applied research, with pioneering developments in the field of porous metal-organic frameworks and delivery systems. He is author of over 178 manuscripts and 6 book chapters. In 2021 and 2022, he got the prestigious ERC Advanced Grant and a second ERC Proof-of-Concept Grant, respectively. In addition, he was awarded an ERC Consolidator Grant in 2014, and his first ERC Proof-of-Concept Grant in 2019. In 2015, he was awarded the Premio Marcial Moreno Mañas Lectureship, and in 2020 he was rewarded with the Research Excellence Award from the Spanish Royal Society of Chemistry.
From the technology transfer side, several technologies and materials developed by his group have been transferred –through licensing patents or signing technology transfer contracts– to various companies. More specifically, Daniel has signed more than 22 research contracts with private companies and has filed 11 patents, from which 4 have been licensed. Moreover, he has been able to signed 4 technology transfer contracts. Interestingly, these technologies have given rise to families of products that are now on the market, as for example LuctaCaps® and Fungipol@CP. He is also co-founder of the spin-off company Ahead Therapeutics.
Dr. Maspoch graduated in Chemistry at the Universitat de Girona and obtained his PhD in Materials Science at the Universitat Autònoma de Barcelona & Institut de Ciència de Materials de Barcelona working in the group of Prof. Jaume Veciana and Prof. Concepció Rovira. He then moved to Northwestern University, where he worked as a postdoctoral fellow in the group of professor Chad A. Mirkin. Since September 2011 he is ICREA Research Professor and Group Leader at the Institut Català de Nanociència i Nanotecnologia (ICN2).